Ellis Investment Partners’s Haemonetics HAE Stock Holding History

Ellis Investment Partners’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-912	Closed	-$67K	–	418
2022 Q3	$67K	Hold	912	–	–	0.02%	350
2022 Q2	$59K	Hold	912	–	–	0.02%	382
2022 Q1	$57K	Hold	912	–	–	0.01%	400
2021 Q4	$48K	Hold	912	–	–	0.01%	430
2021 Q3	$64K	Hold	912	–	–	0.02%	368
2021 Q2	$60K	Hold	912	–	–	0.02%	376
2021 Q1	$101K	Hold	912	–	–	0.03%	292
2020 Q4	$108K	Hold	912	–	–	0.03%	275
2020 Q3	$79K	Hold	912	–	–	0.03%	290
2020 Q2	$81K	Hold	912	–	–	0.03%	281
2020 Q1	$83K	Hold	912	–	–	0.04%	220
2019 Q4	$105K	Hold	912	–	–	0.04%	226
2019 Q3	$113K	Hold	912	–	–	0.04%	211
2019 Q2	$109K	Buy	+912	New	+$89.7K	0.04%	214

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Ellis Investment Partners's HAE Position: Q4 2022 in Review

Ellis Investment Partners sold out of Haemonetics (HAE) in Q4 2022, closing a stake of 912 shares — an estimated $67K sold.

Ellis Investment Partners first reported a position in HAE in Q2 2019 and held it in 14 quarters. The position peaked at $113K in Q3 2019. 292 funds tracked by Wall St. Rank hold HAE as of Q4 2022.

Ellis Investment Partners reported no remaining Haemonetics position as of Q4 2022 after selling out during the quarter.
Ellis Investment Partners sold 912 Haemonetics shares in Q4 2022, an estimated $67K.
Ellis Investment Partners first reported a position in Haemonetics in Q2 2019 and held it in 14 quarters.
Ellis Investment Partners's Haemonetics position peaked at $113K in Q3 2019.
292 funds tracked by Wall St. Rank held Haemonetics as of Q4 2022.

Based on Ellis Investment Partners's 13F filing for Q4 2022, filed 31 Jan 2023.